Skip to content

Svenningsson lab

Translational Research on Neuropharmacology and Movement Disorders

  • Home
  • News
  • Research
    • Pre-Clinical
      • P11 and G protein-coupled receptor function & pharmacology
      • Proteinopathies
    • Clinical
      • Clinical trials and Biomarkers in Parkinsonism
      • Ataxia, spastic paraparesis, chorea and other movement disorders
      • The role of glycemic control in Parkinson’s disease
  • Publications
  • People
    • Core Pre-Clinical Group
    • Core Clinical Group
    • Join our team
    • Alumni
    • Lab Group photos
  • Funding
  • Outreach
  • För Patienter
  • Contact

Tag: Nordtjernan Holding AB

Posted on 7 July 2021

Funding from Nordtjernan Holding AB and the Axel Johnson Group

Professor Per Svenningsson from Karolinska Institutet receives funding for a five-year research project of SEK 38 million from Nordstjernan Holding AB and the Axel Johnson Group.

Read KI press release

Postal Address

Karolinska Institutet
NKS, Bioclinicum
Visionsgatan 4
J5:20 Neuro- Svenningsson
Solna, 171 64

Telephone

+46 851774614

Our Karolinska Institute webpage

https://ki.se/en/cns/per-svenningssons-research-group-0

 

Proudly powered by WordPress